GENPHARMASEC
GENPHARMAVerifiedGENPHARMASEC is a publicly traded security listed on the BSE exchange.
Stock Snapshot & Key Numbers — GENPHARMASEC
Verified Daily CloseOfficial closing price, 1-year price range, valuation multiples, and market value from exchange records.
GENPHARMASEC (GENPHARMA) is a Indian equity security listed on the BSE with ISIN BSE:531592. As of the last recorded market session on Close on 16 Oct 2026, the stock closed at ₹1.07, recording a +0.07 (+7.00%) advance from its previous close of ₹1.00. Over the trailing 52-week trading cycle, GENPHARMA has traded between a 52-week low of ₹0.78 and a 52-week high of ₹1.83, establishing its annual trading channel. In historical performance, GENPHARMASEC has fallen 38.86% over the past 1 year. Period returns across standard measurement intervals include: 1-week: +7%, 1-month: -6.14%, 6-month: -5.31%, 1-year: -38.86%, 3-year: -56.75%, 5-year: -76.27%. Daily reported trading volume reached 6,87,960 equity shares. On key valuation multiples as of 11 Oct 2026, the company trades at a trailing price-to-earnings (P/E) multiple of not meaningful (negative earnings) and a price-to-book (P/B) ratio of 0.9x, with a trailing dividend yield of 0.00%. Its market capitalization stands at ₹55.37 Cr. The company is categorized under the Diversified Indian Equities sector and Public Market Listed Security industry within the Indian equities universe.
Price Chart
Trading Multiples & Ranges
Price boundaries and liquidity distribution.
Past Price Win/Loss Odds (1-Week, 1-Month, 3-Month)
How often this stock rose, stayed flat, or fell over past 21-day holding periods (based on historical data, not a future prediction).
How Outside Factors Affect This Stock (Market, Crude Oil & Currency)
How closely this stock moved with the broader market index, crude oil, and the exchange rate over the past year.
| Factor / Benchmark | 1Y Beta (Sensitivity) | 1Y Correlation (-1 to +1) | What This Means |
|---|---|---|---|
| NIFTY 50 | +1.18 | +0.30 | Trailing 1Y historical sensitivity: a 1% move in NIFTY 50 coincided with a +1.18% co-movement (correlation: 0.30). Descriptive historical relationship, not predictive. |
| USD / INR | -1.61 | -0.23 | Trailing 1Y historical sensitivity: a 1% move in USD / INR coincided with a -1.61% co-movement (correlation: -0.23). Descriptive historical relationship, not predictive. |
| Brent Crude Oil | -0.17 | -0.17 | Trailing 1Y historical sensitivity: a 1% move in Brent Crude Oil coincided with a -0.17% co-movement (correlation: -0.17). Descriptive historical relationship, not predictive. |
| US 10Y Treasury Yield | -0.05 | -0.01 | Trailing 1Y historical sensitivity: a 1% move in US 10Y Treasury Yield coincided with a -0.05% co-movement (correlation: -0.01). Descriptive historical relationship, not predictive. |
How to read Beta & Correlation ( Beta > 1 = wider swings than market; < 1 = calmer )▾
Sensitivities measure historical 1-year regression beta and correlation across paired daily trading sessions over the past 252 trading days. Past relationships can shift over time and do not guarantee future co-movement.
Trailing Returns Breakdown
Calendar-aligned historical percentage performance across standard market windows.
| Period | Start Price | Current Price | Return (%) |
|---|---|---|---|
| 1 Week | ₹1.00 | ₹1.07 | +7.00% |
| 15 Days | ₹1.07 | ₹1.07 | +0.00% |
| 1 Month | ₹1.14 | ₹1.07 | -6.14% |
| 3 Months | ₹1.04 | ₹1.07 | +2.88% |
| 6 Months | ₹1.13 | ₹1.07 | -5.31% |
| 1 Year | ₹1.75 | ₹1.07 | -38.86% |
| 3 Years | ₹2.47 | ₹1.07 | -56.75% |
| 5 Years | ₹4.51 | ₹1.07 | -76.27% |
Price Swings & Biggest Historical Drops
How much this stock typically fluctuates and its largest peak-to-bottom drops over 1 and 5 years.
Calendar-Year Historical Performance
Annual performance breakdown comparing first and last closing sessions of each calendar year.
| Calendar Year | Start Close | End Close | Annual Return | Trajectory Bar |
|---|---|---|---|---|
| CY 2026 | ₹1.29 | ₹1.07 | -17.1% | |
| CY 2025 | ₹3.36 | ₹1.31 | -61.0% | |
| CY 2024 | ₹2.86 | ₹3.08 | +7.8% | |
| CY 2023 | ₹2.45 | ₹2.80 | +14.5% | |
| CY 2022 | ₹3.63 | ₹2.49 | -31.5% | |
| CY 2021 | ₹4.51 | ₹3.15 | -30.1% |
Historical Investment Simulator
Factual simulation of past returns in GENPHARMASEC (GENPHARMA) using real recorded closing prices.
Corporate Actions History
No dividend or stock split distributions recorded in historical feeds for GENPHARMA.
Recent News & Official Exchange Announcements
Official exchange filings, order wins, and company updates. Click any announcement to see how it affects the business on the right.
Genpharmasec standalone profit rises to ₹156.96 lakh in Q1FY27 - scanx.trade
Genpharmasec standalone profit rises to ₹156.96 lakh in Q1FY27 scanx.trade
Genpharmasec discloses 34th AGM voting results; all resolutions pass - scanx.trade
Genpharmasec discloses 34th AGM voting results; all resolutions pass scanx.trade
Genpharmasec Ltd files FY26 annual report with BSE - scanx.trade
Genpharmasec Ltd files FY26 annual report with BSE scanx.trade
Genpharmasec promoter Rajesh Sadhwani buys 50 lakh shares - scanx.trade
Genpharmasec promoter Rajesh Sadhwani buys 50 lakh shares scanx.trade
Why This Matters for the Business
Plain-English breakdown of how the selected announcement connects to revenue, costs, and business drivers.
Financial performance outpaced historical baseline, driving operating leverage and valuation re-rating.
- •Financial performance and operating margins expanded ahead of consensus projections
Volume throughput absorbs fixed manufacturing plant overheads, supporting operating EBITDA margins and cash generation across diversified indian equities units.
Continuous commercial tenders and capital expenditures lock in forward order book-to-bill expansion.
At-a-Glance Health & Momentum Check
While recent announcements reflect past operations, profit margins and return on capital have been tightening as the business absorbs higher costs or new expansion spending.
Peer & Sector Comparison — Next Research Steps
Exit points and comparative equity universe: same-sector peers, shared macro sensitivity betas, and your watchlist.
Common Questions About GENPHARMASEC (GENPHARMA)
Key facts on GENPHARMA share price, historical returns, valuation ratios, and past SIP performance.
What is the current share price and 52-week range of GENPHARMASEC (GENPHARMA)?
As of 16 Oct 2026, the official closing share price of GENPHARMASEC (GENPHARMA) on BSE is ₹1.07 (+7.00% vs the previous close). Over the past 52 weeks, GENPHARMA has traded between a low of ₹0.78 and a high of ₹1.83, with a reported market capitalization of ₹55.37 Cr.
What are the historical returns of GENPHARMASEC (GENPHARMA)?
Based on split-adjusted closing prices through 16 Oct 2026, GENPHARMASEC (GENPHARMA) recorded the following trailing price returns: 1 Week: +7.00% (from ₹1.00 to ₹1.07); 15 Days: +0.00% (from ₹1.07 to ₹1.07); 1 Month: -6.14% (from ₹1.14 to ₹1.07); 3 Months: +2.88% (from ₹1.04 to ₹1.07); 6 Months: -5.31% (from ₹1.13 to ₹1.07); 1 Year: -38.86% (from ₹1.75 to ₹1.07); 3 Years: -56.75% (from ₹2.47 to ₹1.07); 5 Years: -76.27% (from ₹4.51 to ₹1.07). Past performance reflects historical exchange records and does not predict future returns.
What is the P/E ratio, P/B ratio, and dividend yield of GENPHARMASEC (GENPHARMA)?
GENPHARMASEC (GENPHARMA) currently trades at a trailing Price-to-Earnings (P/E) ratio of not applicable (or negative trailing earnings), a Price-to-Book (P/B) ratio of 0.9x, and a trailing 12-month dividend yield of 0.00%. It operates in the Diversified Indian Equities sector (Public Market Listed Security).
How much would a past lump-sum or monthly SIP investment in GENPHARMA have grown?
Based on historical closing prices for GENPHARMASEC (GENPHARMA): A one-time lump-sum investment of ₹1,00,000.00 held for 5 years would be worth ₹23,727.96 (-76.3% total return, -25.0% CAGR), while a monthly SIP of ₹10,000.00 over 5 years (total invested: ₹6,10,000.00) would be worth ₹3,13,371.65 (-48.6% absolute return). You can test custom amounts and holding periods in the interactive calculator above.
Official Corporate Perspective
Authorized Investor Relations officers may submit authenticated context or coordinate with our research team.